Comparative Pharmacology
Head-to-head clinical analysis: IMPOYZ versus ZURAGARD.
Peer-Reviewed Evidence
Head-to-head clinical analysis: IMPOYZ versus ZURAGARD.
IMPOYZ vs ZURAGARD
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
IMPOYZ is a monoclonal antibody that binds to and inhibits the activity of interleukin-23 (IL-23), a cytokine involved in inflammatory and immune responses. By blocking IL-23, it reduces the production of pro-inflammatory cytokines and attenuates the inflammatory cascade.
ZURAGARD (zagociguat) is a soluble guanylate cyclase (sGC) stimulator that enhances the sensitivity of sGC to nitric oxide (NO) and directly stimulates sGC independently of NO, leading to increased cyclic guanosine monophosphate (cGMP) production. This results in vasodilation and improved hemodynamics.
100 mg orally twice daily
16 mg/kg intravenously every 12 hours for 2 days, followed by 8 mg/kg intravenously every 12 hours for 3 days.
None Documented
None Documented
Terminal elimination half-life 6–8 hours in adults with normal renal function; prolonged to 15–30 hours in severe renal impairment (CrCl <30 mL/min).
Terminal elimination half-life is approximately 14-18 hours in healthy adults, allowing once-daily dosing; may be prolonged in renal impairment (up to 40 hours in severe impairment).
Primarily renal (70–80% as unchanged drug via glomerular filtration and tubular secretion); biliary/fecal (15–20%) with minor hepatic metabolism.
Primarily renal excretion (60-70% as unchanged drug); biliary/fecal elimination accounts for 20-30%.
Category C
Category C
Unknown
Unknown